Update on the pathogenesis, diagnosis and therapy of AIDS-related lymphoma

Current Infectious Disease Reports

Volumn 5, Issue 2, 2003, Pages 176-184

  Little, Richard F ^a   Wilson, Wyndham H ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ASPARAGINASE; BLEOMYCIN; CD20 ANTIBODY; CD4 ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; METHOTREXATE; MONOCLONAL ANTIBODY; MYC PROTEIN; PREDNISOLONE; PREDNISONE; PROTEIN BCL 2; PROTEIN BCL 6; RITUXIMAB; SYNDECAN 1; TUMOR MARKER; VINCRISTINE; VINDESINE;

AIDS RELATED COMPLEX; B CELL LYMPHOMA; BONE MARROW BIOPSY; BURKITT LYMPHOMA; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER STAGING; CEREBROSPINAL FLUID ANALYSIS; EPSTEIN BARR VIRUS; GENE MUTATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTOPATHOLOGY; HUMAN; LARGE CELL LYMPHOMA; LYMPHOMA; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; NONHODGKIN LYMPHOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; POLYMERASE CHAIN REACTION; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIMARY EFFUSION LYMPHOMA; REVIEW; SCINTISCANNING;

EID: 0142076252     PISSN: 15233847     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11908-003-0055-1     Document Type: Review

References (81)

1. Mocroft AJ, Lundgren JD, d'Armino Monforte A, et al.: Survival of AIDS patients according to type of AIDS-defining event. The AIDS in Europe Study Group. Int J Epidemiol 1997, 26:400-407.
2. Kaplan LD, Straus DJ, Testa MA, et al.: Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N Engl J Med 1997, 336:1641-1648.
3. Dore GJ, Li Y, McDonald A, et al.: Impact of highly active antiretroviral therapy on individual AIDS- defining illness incidence and survival in Australia. J Acquir Immune Defic Syndr 2002, 29:388-395.
4. Besson C, Goubar A, Gabarre J, et al.: Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy. Blood 2001, 98:2339-2344.
5. Karp JE, Broder S: The pathogenesis of AIDS lymphomas: a foundation for addressing the challenges of therapy and prevention. Leuk Lymphoma 1992, 8:167-188.
6. Biemer JJ: Malignant lymphomas associated with immunodeficiency states. Ann Clin Lab Sci 1990, 20:175-191.
7. Gaspar B, Sharifi R, Kinnon C, et al.: Sap gene transfer restores cytotoxic function in EBV-CTLS generated from individuals with XLP. Paper presented at American Society of Hematology Annual Meeting. Orlando, FL. December 7-11, 2001.
8. Gruhn B, Meerbach A, Häfer R, et al.: Early diagnosis and preemptive therapy of Epstein-Barr virus-associated lymphoproliferative disease following hematopoietic stem cell transplantation. Paper presented at American Society of Hematology Annual Meeting. Orlando, FL. December 7-11, 2001.
9. Savoldo B, Gross J, Karpen S, et al.: Humanized anti-CD20 monoclonal antibody for the treatment of lymphoproliferative disease developing in pediatric solid organ transplant recipients. Paper presented at Sixth International Conference on Malignancies in AIDS & Other Immunodeficiencies: Basic, Epidemiologic & Clinical Research. Bethesda, MD. April 22-24, 2002.
10. Liu Z, Savoldo B, Huls H, et al.: Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the prevention and treatment of EBV-associated post-transplant lymphomas. Recent Results Cancer Res 2002, 159:123-133.
11. Kamel OW, van de Rijn M, Weiss LM, et al.: Reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis. N Engl J Med 1993, 328:1317-1321.
12. Montalban C, Manzanal A, Boixeda D, et al.: Helicobacter pylori eradication for the treatment of low-grade gastric MALT lymphoma: follow-up together with sequential molecular studies. Ann Oncol 1997, 8(Suppl 2):37-39.
13. Levine AM, Shibata D, Sullivan-Halley J, et al.: Epidemiological and biological study of acquired immunodeficiency syndrome-related lymphoma in the County of Los Angeles: preliminary results. Cancer Res 1992, 52(19 Suppi):5482s-5484s.
14. Knowles DM: Etiology and pathogenesis of AIDS-related non-Hodgkin's lymphoma. Hematol Oncol Clin North Am 1996, 10:1081-1090.
15. Kalter SP, Riggs SA, Cabanillas F, et al.: Aggressive non-Hodgkin's lymphomas in immunocompromised homosexual males. Blood 1985, 66:655-659.
16. Ziegler JL, Miner RC, Rosenbaum E, et al.: Outbreak of Burkitt's-like lymphoma in homosexual men. Lancet 1982, 2:631-633.
17. Jaffe ES, Harris NL, Stein H, Vardiman JW: World Health Organization Classification of Tumors: Pathology & Genetics: Tumors of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2001.
18. Rosenwald A, Wright G, Chan WC, et al.: The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002, 346:1937-1947.
19. Alizadeh AA, Eisen MB, Davis RE, et al.: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000, 403:503-511.
20. Carbone A, Gloghini A, Larocca LM, et al.: Expression profile of MUM1/IRF4, BCL-6, and CD138/syndecan-1 defines novel histogenetic subsets of human immunodeficiency virus-related lymphomas. Blood 2001, 97:744-751.
21. Schlaifer D, Brousset P, Attal M, et al.: bcl-2 Proto-oncogene and Epstein-Barr virus latent membrane protein-1 expression in AIDS-related lymphoma. Histopathology 1994, 25:77-82.
22. Gaidano G, Pastore C, Volpe G: Molecular pathogenesis of non-Hodgkin lymphoma: a clinical perspective. Haematologica 1995, 80:454-472.
23. Gascoyne RD, Adomat SA, Krajewski S, et al.: Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood 1997, 90:244-251.
24. Kramer MH, Hermans J, Wijburg E, et al.: Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. Blood 1998, 92:3152-3162.
25. Gaidano G, Pastore C, Lanza C, et al.: Molecular pathology of AIDS-related lymphomas. Biologic aspects and clinicopathologic heterogeneity. Ann Hematol 1994, 69:281-290.
26. Pluda JM, Venzon DJ, Tosato G, et al.: Parameters affecting the development of non-Hodgkin's lymphoma in patients with severe human immunodeficiency virus infection receiving antiretroviral therapy. J Clin Oncol 1993, 11: 1099-1107.
27. Nador RG, Cesarman E, Chadburn A, et al.: Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus. Blood 1996, 88: 645-656.
28. Yawetz S, Cumberland WG, van der Meyden M, Martinez-Maza O: Elevated serum levels of soluble CD23 (sCD23) precede the appearance ofacquired immunodeficiency syndrome-associated non-Hodgkin's lymphoma. Blood 1995, 85:1843-1849.
29. Widney D, Gundapp G, Said JW, et al.: Aberrant expression of CD27 and soluble CD27 (sCD27) in HIV infection and in AIDS-associated lymphoma. Clin Immunol 1999, 93:114-123.
30. Bossolasco S, Nilsson A, de Milito A, et al.: Soluble CD23 in cerebrospinal fluid: a marker of AIDS-related non-Hodgkin's lymphoma in the brain. AIDS 2001, 15:1109-1113.
31. Cote TR, Biggar RJ, Rosenberg PS, et al.: Non-Hodgkin's lymphoma among people with AIDS: incidence, presentation and public health burden. AIDS/Cancer Study Group. Int J Cancer 1997, 73:645-650.
32. Franceschi S, Dal Maso L, La Vecchia C: Advances in the epidemiology of HIV-associated non-Hodgkin's lymphoma and other lymphoid neoplasms. Int J Cancer 1999, 83:481-485.
33. Antinori A, De Rossi G, Ammassari A, et al.: Value of combined approach with thallium-201 single-photon emission computed tomography and Epstein-Barr virus DNA polymerase chain reaction in CSF for the diagnosis of AIDS-related primary CNS lymphoma. J Clin Oncol 1999, 17:554-560.
34. Centers for Disease Control: Revision of the case definition of acquired immunodeficiency syndrome for national reporting - United States. MMWR 1985, 34:373-375.
35. Cinque P, Brytting M, Vago L, et al.: Epstein-Barr virus DNA in cerebrospinal fluid from patients with AIDS-related primary lymphoma of the central nervous system, Lancet 1993, 342:398-401.
36. Parravicini C, Chandran B, Corbellino M, et al.: Differential viral protein expression in Kaposi's sarcoma-associated herpesvirus-infected diseases: Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease. Am J Pathol 2000, 156:743-749.
37. Dana BW, Dahlberg S, Miller TP, et al.: m-BACOD treatment for intermediate- and high-grade malignant lymphomas: a Southwest Oncology Group phase II trial. J Clin Oncol 1990, 8: 1155-1162.
38. Walsh C, Wernz JC, Levine A, et al.: Phase I trial of m-BACOD and granulocyte macrophage colony stimulating factor in HIV-associated non-Hodgkin's lymphoma. J Acquir Immune Defic Syndr 1993, 6:265-271.
39. Levine AM, Wernz JC, Kaplan L, et al.: Low-dose chemotherapy with central nervous system prophylaxis and zidovudine maintenance in AIDS-related lymphoma. A prospective multi-institutional trial. JAMA 1991, 266: 84-88.
40. Fisher RI, Gaynor ER, Dahlberg S, et al.: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993, 328:1002-1006.
41. Wilson WH: Chemotherapy for AIDS-related lymphomas [letter; comment]. N Engl J Med 1997, 337:1172-1174.
42. Ratner L, Redden D, Hamzeh F, et al.: Chemotherapy for HIV-NHL in combination with HAART. Paper presented at 3rd National AIDS Malignancy Meeting. Bethesda, MD. May 26-28, 1999.
43. Antinori A, Cingolani A, Alba L, et al.: Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy. AIDS 2001, 15:1483-1491.
44. Levine AM, Sullivan-Halley J, Pike MC, et al.: Human immunodeficiency virus-related lymphoma. Prognostic factors predictive of survival. Cancer 1991, 68:2466-2472.
45. Straus DJ, Huang J, Testa MA, et al.: Prognostic factors in the treatment of human immunodeficiency virus- associated non-Hodgkin's lymphoma: analysis of AIDS Clinical Trials Group protocol 142-low-dose versus standard-dose m-BACOD plus granulocyte-macrophage colony-stimulating factor. National Institute of Allergy and Infectious Diseases. J Clin Oncol 1998, 16:3601-3606.
46. Levine AM: AIDS-associated malignant lymphoma. Med Clin North Am 1992, 76:253-268.
47. Vaccher E, Spina M, di Gennaro G, et al.: Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma. Cancer 2001, 91:155-163.
48. Ratner L, Lee J, Tang S, et al.: Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy. J Clin Oncol 2001, 19:2171-2178.
49. Spina M, Vaccher E, Juzbasic S, et al.: Human immunodeficiency virus-related non-Hodgkin lymphoma: activity of infusional cyclophosphamide, doxorubicin, and etoposide as second-line chemotherapy in 40 patients. Cancer 2001, 92: 200-206.
50. Tirelli U, Spina M, Jaeger U, et al.: Infusional CDE with rituximab for the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma: preliminary results of a phase I/II study. Recent Results Cancer Res 2002, 159:149-153.
51. Mackall CL, Fleisher TA, Brown MR, et al.: Lymphocyte depletion during treatment with intensive chemotherapy for cancer. Blood 1994, 84:2221-2228.
52. Phenix BN, Lum JJ, Nie Z, et al.: Antiapoptotic mechanism of HIV protease inhibitors: preventing mitochondrial transmembrane potential loss. Blood 2001, 98:1078-1085.
53. Mellors JW, Rinaldo CR Jr, Gupta P, et al.: Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996, 272:1167-1170.
54. Little R, Pearson D, Gutierrez M, et al.: Dose-adjusted EPOCH chemotherapy (CT) with suspension of antiretroviral therapy (ART) for HIV-associated non-Hodgkin's lymphoma (HIV-NHL). Paper presented at 4th International AIDS Malignancy Conference. Bethesda, MD. May 16-18, 2000.
55. Raphael M, Lamine M, Abd Alsamad I, et al.: Non-Hodgkin's lymphoma and AIDS: histopathologic features. Arch Anat Cytol Pathol 1992, 40:105-109.
56. Bauer KD, Merkel DE, Winter JN, et al.: Prognostic implications of ploidy and proliferative activity in diffuse large cell lymphomas. Cancer Res 1986, 46:3173-3178.
57. Miller TP, Grogan TM, Dahlberg S, et al.: Prognostic significance of the Ki-67-associated proliferative antigen in aggressive non-Hodgkin's lymphomas: a prospective Southwest Oncology Group trial. Blood 1994, 83:1460-1466.
58. Wilson WH, Teruya-Feldstein J, Fest T, et al.: Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin's lymphomas. Blood 1997, 89:601-609.
59. Tulpule A, Sherrod A, Dharmapala D, et al.: Multidrug resistance (MDR-1) expression in aids-related lymphomas. Leuk Res 2002, 26:121-127.
60. Lai GM, Chen YN, Mickley LA, et al.: P-glycoprotein expression and schedule dependence of adriamycin cytotoxicity in human colon carcinoma cell lines. Int J Cancer 1991, 49:696-703.
61. Vose JM, Link BK, Grossbard ML, et al.: Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol 2001, 19:389-397.
62. Mackall CL, Fleisher TA, Brown MR, et al.: Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy. N Engl J Med 1995, 332:143-149.
63. Levine AM: Epidemiology, clinical characteristics, and management of AIDS-related lymphoma. Hematol Oncol Clin North Am 1991, 5:331-342.
64. Winceslaus J: Regression of AIDS-related pleural effusion with HAART. Highly active antiretroviral therapy [letter]. Int J STD AIDS 1998, 9:368-370.
65. Raez LE, Patel P, Feun L, et al.: Natural history and prognostic factors for survival in patients with acquired immune deficiency syndrome (AIDS)-related primary central nervous system lymphoma (PCNSL). Crit Rev Oncog 1998, 9:199-208.
66. Ling SM, Roach M III, Larson DA, Wara WM: Radiotherapy of primary central nervous system lymphoma in patients with and without human immunodeficiency virus. Ten years of treatment experience at the University of California San Francisco. Cancer 1994, 73:2570-2582.
67. Hoffmann C, Tabrizian S, Wolf E, et al.: Survival of AIDS patients with primary central nervous system lymphoma is dramatically improved by HAART-induced immune recovery. AIDS 2001, 15:2119-2127.
68. Montesinos-Rongen M, Kuppers R, Schluter D, et al.: Primary central nervous system lymphomas are derived from germinal-center B cells and show a preferential usage of the V4-34 gene segment. Am J Pathol 1999, 155:2077-2086.
69. Forsyth PA, Yahalom J, DeAngelis LM: Combined-modality therapy in the treatment of primary central nervous system lymphoma in AIDS. Neurology 1994, 44:1473-1479.
70. Singhal D, Witham TF, Germanwala A, et al.: Multi-modality therapy leads to longer survival in primary central nervous system lymphoma patients. Can J Neurol Sci 2002, 29:147-153.
71. Jacomet C, Girard PM, Lebrette MG, et al.: Intravenous methotrexate for primary central nervous system non- Hodgkin's lymphoma in AIDS. AIDS 1997, 11:1725-1730.
72. Hanel M, Fiedler F, Thorns C: Anti-CD20 monoclonal antibody (Rituximab) and Cidofovir as successful treatment of an EBV-associated lymphoma with CNS involvement. Onkologie 2001, 24:491-494.
73. Little RF, Gutierrez M, Jaffe ES, et al.: HIV-associated non-Hodgkin lymphoma: incidence, presentation, and prognosis. JAMA 2001, 285:1880-1885.
74. Gisselbrecht C, Oksenhendler E, Tirelli U, et al.: Human immunodeficiency virus-related lymphoma treatment with intensive combination chemotherapy. French-Italian Cooperative Group. Am J Med 1993, 95:188-196.
75. Sparano JA, Wiernik PH, Strack M, et al.: Infusional cyclophosphamide, doxorubicin and etoposide in HIV-related non-Hodgkin's lymphoma: a follow-up report of a highly active regimen. Leuk Lymphoma 1994, 14:263-271.
76. Little RF, Pearson D, Steinberg S, et al.: Dose-adjusted epoch chemotherapy (CT) in previously untreated HIV-associated non-Hodgkin's lymphoma (HIV-NHL). Paper presented at American Society of Clinical Oncology 35th Annual Meeting. Atlanta. May 15-18, 1999.
77. Ballerini P, Gaidano G, Gong J, et al.: Molecular pathogenesis of HIV-associated lymphomas. AIDS Res Hum Retroviruses 1992, 8:731-735.
78. Ballerini P, Gaidano G, Gong JZ, et al.: Multiple genetic lesions in acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma. Blood 1993, 81:166-176.
79. Carbone A, Gaidano G, Gloghini A, et al.: Differential expression of BCL-6, CD138/syndecan-1, and Epstein-Barr virus-encoded latent membrane protein-1 identifies distinct histogenetic subsets of acquired immunodeficiency syndrome-related non-Hodgkin's lymphomas. Blood 1998, 91:747-755.
80. Delecluse HJ, Raphael M, Magaud JP, et al.: Variable morphology of human immunodeficiency virus-associated lymphomas with c-myc rearrangements. The French Study Group of Pathology for Human Immunodeficiency Virus-Associated Tumors, I. Blood 1993, 82:552-563.
81. Martin A, Flaman JM, Frebourg T, et al.: Functional analysis of the p53 protein in AIDS-related non-Hodgkin's lymphomas and polymorphic lymphoproliferations. Br J Haematol 1998, 101:311-317.